Left Ventricular Assist Devices

A left ventricular assist device (LVAD) is a pump for patients with advanced heart failure. Once implanted, the device is designed to help the left ventricle of your patient’s heart pump blood to the rest of their body. LVADs can be used as bridge-to-transplant therapy and/or destination therapy. LVADs are an important therapy option for patients with Class IIIB or IV heart failure. The LVAD you choose can impact your patient's quality of life.

HeartMate 3 Left Ventricular Assist Device (LVAD)

The HeartMate 3™ Left Ventricular Assist Device is indicated for short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in patients with advanced refractory left ventricular heart failure. HeartMate 3 LVAD with Full MagLev™ Flow Technology delivers unprecedented* survival and safety outcomes as demonstrated in the MOMENTUM 3 Trial at 2 years.^1**

HeartMate II Left Ventricular Assist Device

The HeartMate II™ LVAD is designed to provide short- or long-term circulatory support for advanced heart failure patients and is indicated for both destination therapy and bridge-to-transplantation in the United States. Backed by more than 10 years of data, the HeartMate II LVAD is the most widely used and extensively studied LVAD in the world, with more than 27,000 patients implanted worldwide.^2,3

Manuals & Technical Resources

Cardiovascular Products

Customer Service

This device is commercially available for use in select international markets.

References

*Based on HeartMate 3™ LVAD highest published survival and lowest published stroke and thrombosis rates in a randomized controlled trial in the continuous-flow LVAD category of devices in the U.S.^1,2-6

**HeartMate 3™ LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.

Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
Abbott data on file as of July 20, 2020.
Based on clinical and device tracking data as of June 9, 2020.
Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, ... Gregoric ID. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med. 2017;376(5):451-460.
Markham DW. Two-year Outcomes in the ENDURANCE Supplemental Trial. American Heart Association (AHA) Annual Meeting; November 10, 2018; Chicago, IL.
Uriel N. Long-Term Burden of Hemocompatibility Related Adverse Events in the MOMENTUM 3 Trial: Final Analysis of the 1028 Patient Cohort. The International Society for Heart & Lung Transplantation (ISHLT) Annual Meeting; April 4, 2019; Orlando, FL.

MAT-2009011 v1.0

CARDIOVASCULAR

Left Ventricular Assist Devices